Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

Rhea-AI Summary

Bausch Health (NYSE: BHC) announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb (NYSE: BLCO), effective August 5, 2026. Bausch + Lomb is described as a key asset of Bausch Health.

Additional directors Robert J. Chersi, Laurence E. Paul, M.D., and Barbara J. Trebbi also joined the Bausch + Lomb board. They replace Steven Collis, Karen Ling, Thomas Ross and Andrew von Eschenbach, MD, who resigned without any stated disagreements with Bausch + Lomb. Bausch Health remains Bausch + Lomb’s largest shareholder, indirectly holding about 87% of its outstanding common shares, and requested these board changes in line with its ownership position.

Market Context

Recent BLCO announcements produced both positive and negative 24-hour reactions, adding a mixed hist...

Analysis

Recent BLCO announcements produced both positive and negative 24-hour reactions, adding a mixed historical backdrop to this governance event. Current short positioning was categorized as low; the board transition remained the primary item to monitor.

Key Figures

Effective date: August 5, 2026 Ownership stake: 87%

2 metrics

Effective date August 5, 2026 Bausch + Lomb board appointments

Ownership stake 87% Bausch Health ownership of Bausch + Lomb common shares

Historical Context

5 past events · Latest: Jul 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 16	Product launch	Positive	+3.3%	U.S. launch of EyeGility preloaded IOL delivery system
Jul 09	Phase 2 results	Negative	-3.0%	BL1107 missed primary and key secondary visual function endpoints
Jul 09	Platform launch	Positive	+0.4%	Launch of Orphia AI-powered digital health platform
Jul 06	Earnings scheduling	Neutral	-0.3%	Company scheduled release of second-quarter 2026 financial results
Jul 01	Survey data	Positive	-0.1%	Dry eye survey linked symptom relief with improved quality of life

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive and negative announcements produced mixed alignment between BLCO news sentiment and subsequent price reactions.

Key Terms

outstanding common shares

1 terms

outstanding common shares financial

"holding approximately 87% of its outstanding common shares indirectly"

The total number of a company’s common stock shares that have been issued and are currently held by outside shareholders, excluding any shares the company has bought back and holds in treasury. It matters because it determines ownership slices and is used to calculate key per-share metrics like market capitalization and earnings per share—think of the company as a pizza and outstanding shares as the number of slices held by others.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corporation (NYSE: BLCO)(TSX: BLCO), a subsidiary of Bausch Health Companies Inc., effective August 5, 2026.

"Bausch + Lomb is an important asset of Bausch Health, and I look forward to working with the board to support its strategy and help drive long-term value for shareholders," said Thomas J. Appio.

In addition, Robert J. Chersi, Laurence E. Paul, M.D., and Barbara J. Trebbi have joined the Bausch + Lomb board of directors. The new directors replace Steven Collis, Karen Ling, Thomas Ross and Andrew von Eschenbach, MD, each of whom has tendered their resignation in order to facilitate the new appointments; none of the resignations were the result of any disagreement with Bausch + Lomb.

Bausch Health is Bausch + Lomb's largest shareholder, holding approximately 87% of its outstanding common shares indirectly through its wholly owned subsidiaries. The Company continues to support Bausch + Lomb's strategy and long-term growth objectives.

These Board changes were requested by Bausch Health and are consistent with its existing ownership position in Bausch + Lomb.

Forward-looking Statements

This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. Such statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

Investor Contact:	Media Contact:
Garen Sarafian	Katie Savastano
ir@bauschhealth.com	corporate.communications@bauschhealth.com
(877) 281-6642 (toll free)	(908) 569-3692
BHC-ORGANIZATION

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-ceo-thomas-j-appio-joins-bausch--lomb-board-302844911.html

SOURCE Bausch Health Companies Inc.

FAQ

What board change did Bausch Health (BHC) announce involving Bausch + Lomb (BLCO) in August 2026?

Bausch Health announced its CEO, Thomas J. Appio, joined the Bausch + Lomb board effective August 5, 2026. According to Bausch Health, this aligns with its role as majority shareholder and supports Bausch + Lomb’s strategy and long-term value creation for shareholders.

Which new directors joined the Bausch + Lomb (BLCO) board alongside Bausch Health (BHC) CEO Thomas J. Appio?

Alongside Thomas J. Appio, Robert J. Chersi, Laurence E. Paul, M.D., and Barbara J. Trebbi joined the Bausch + Lomb board. According to Bausch Health, these appointments follow coordinated resignations by four prior directors to facilitate the new board composition.

Which Bausch + Lomb (BLCO) directors resigned in 2026 and was there any reported disagreement?

Steven Collis, Karen Ling, Thomas Ross and Andrew von Eschenbach, MD, resigned from the Bausch + Lomb board. According to Bausch Health, the resignations were to facilitate new appointments and were not the result of any disagreement with Bausch + Lomb.

How much of Bausch + Lomb (BLCO) does Bausch Health (BHC) own after the 2026 board changes?

Bausch Health remains Bausch + Lomb’s largest shareholder, indirectly holding approximately 87% of its outstanding common shares. According to Bausch Health, this ownership is held through wholly owned subsidiaries and underpins its role in requesting the board changes.

Why did Bausch Health (BHC) request changes to the Bausch + Lomb (BLCO) board of directors?

Bausch Health requested the Bausch + Lomb board changes as part of its governance role as majority owner. According to Bausch Health, the adjustments are consistent with its approximately 87% ownership and its support for Bausch + Lomb’s strategy and long-term growth objectives.

What does Thomas J. Appio’s appointment to the Bausch + Lomb (BLCO) board mean for shareholders of Bausch Health (BHC)?

Thomas J. Appio said he aims to support Bausch + Lomb’s strategy and long-term shareholder value as a board member. According to Bausch Health, aligning leadership and board representation reflects its view of Bausch + Lomb as an important asset within the group.